Skip to main content

Table 1 Cohort demographics

From: Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease

Cohort

Group

n (F/M)

Age

MMSE

1-42/1-40

P-tau181

T-tau

TRIAD CSF

Young

5 (3/2)

23 (1, 22–24)a,b,c,d

30 (0, 30–30)

0.095 (0.010, 0.088–0.10)b,d

24 (7, 23–31)b

191 (36, 161–222)b

 

CU−

15 (11/4)

71 (5, 68–74)a

29 (1, 28–30)

0.093 (0.010, 0.082–0.098)b,d

33 (10, 29–42)b

252 (72, 199–335)b

 

CU+6

10 (5/5)

73 (3, 70–76)a

29 (1, 29–30)

0.059 (0.011, 0.046–0.067)a,b

52 (22, 41–72)b

395 (126, 292–488)b

 

CI−

12 (6/6)

65 (8, 60–68)

29 (3, 26–30)

0.095 (0.014, 0.091–0.099)b

33 (13, 19–36)b

250 (88, 159–294)b

 

CI+8

28 (11/17)

68 (9, 60–77)

25 (4, 21–29)

0.042 (0.009, 0.037–0.051)

82 (50, 64–118)

551 (323, 398–778)

  1. Notes: Detailed diagnosis for the CI+ group consisted of the following: 15 AD and 13 MCI, while the CI− group consisted of 3 MCI, 4 FTD, and 5 patients with uncertain diagnosis. Analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for the continuous variables. The level of significance used was p ≤ 0.05. Data presented as median (standard deviation, interquartile interval) and in ng/L. aSignificant ANOVA post hoc Tukey test compared to CI−. bSignificant ANOVA post hoc Tukey test compared to CI+. cSignificant ANOVA post hoc Tukey test compared to CU−. dSignificant ANOVA post hoc Tukey test compared to CU+
  2. Abbreviations: MMSE Mini-Mental State Exam Score, 1-42/1-40 amyloid beta protein ratio 1-42/1-40, P-tau181 total tau, T-tau phosphorylated tau at amino acid Thr181, CU− cognitively unimpaired Aβ negative, CU+ cognitively unimpaired Aβ positive, CI− cognitively impaired Aβ negative, CI+ cognitively impaired Aβ positive